文献速递慢性肾脏病

无糖尿病白蛋白尿性慢性肾脏病患者联合RAAS与SGLT2抑制剂治疗的估计终身获益

Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-11-22

该研究基于试验水平效应估计,在无糖尿病白蛋白尿性慢性肾脏病患者中,联合使用ACEI/ARB与SGLT2抑制剂相比未治疗可显著延长无主要复合终点事件的生存时间。50岁患者至75岁期间,联合治疗组无事件生存17.0年,未治疗组9.6年,获益7.4年;假设较低依从性和较弱疗效时,获益为5.3至5.8年。

要点

  • 无糖尿病白蛋白尿性慢性肾脏病患者中,联合ACEI/ARB与SGLT2抑制剂估计可大幅延长无肾功能衰竭生存。
  • 50岁患者至75岁,联合治疗组无主要复合终点生存17.0年,未治疗组9.6年,获益7.4年。
  • 假设较低依从性和较弱疗效时,无事件生存获益为5.3至5.8年。

核心结论

  • 在无糖尿病白蛋白尿性慢性肾脏病患者中,联合ACEI/ARB与SGLT2抑制剂治疗预计可大幅增加无肾功能衰竭生存。

研究设计与样本

  • 使用ACEI/ARB(雷米普利/贝那普利;n=690)和SGLT2抑制剂(达格列净;n=1398)与安慰剂对照的试验水平效应估计,推导联合治疗相比未治疗的效应。
  • 将该效应应用于DAPA-CKD试验中无糖尿病白蛋白尿性慢性肾脏病活跃治疗组患者(n=697),预测联合治疗与未治疗的无事件生存和总生存。
  • 计算时预设较低依从性和较临床试验观察到的更弱获益。

主要发现

  • 联合ACEI/ARB与SGLT2抑制剂对比未治疗的主要终点汇总估计风险比为0.35(95%CI 0.30至0.41)。
  • 50岁患者至75岁,联合治疗组无主要复合终点生存17.0年(95%CI 12.4至19.6),未治疗组9.6年(95%CI 8.4至10.7),无事件生存获益7.4年(95%CI 6.4至8.7)。
  • 假设较低依从性和较弱疗效时,无事件生存获益范围为5.3年(95%CI 4.4至6.1)至5.8年(95%CI 4.8至6.8)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Despite high rates of complications in patients with CKD without diabetes, the implementation of proven therapies in this group remains low. Expressing the clinical benefit of a therapy in terms of extra years free from the disease or death may facilitate implementation. We estimated lifetime survival free of kidney failure for patients with albuminuric CKD without diabetes treated with the combination therapy of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and sodium-glucose cotransporter-2 (SGLT2) inhibitors relative to patients not treated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used trial-level estimates of the effect of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ramipril/benazepril; n=690) and SGLT2 inhibitors (dapagliflozin; n=1398) compared with placebo to derive the effect of combination therapy versus no treatment. Using this effect, we estimated treatment effect of combination therapy to the active treatment group of patients with albuminuric CKD without diabetes participating in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (n=697) and projected eventfree and overall survival for those treated and not treated with combination therapy. We also performed our calculations anticipating lower adherence and less pronounced benefits than were observed in the clinical trials. The primary outcome was a composite of doubling of serum creatinine, kidney failure, or death. RESULTS: The aggregate estimated hazard ratio comparing combination therapy with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and SGLT2 inhibitor versus no treatment for the primary end point was 0.35 (95% confidence interval, 0.30 to 0.41). For a 50-year-old patient until the age of 75 years, the estimated survival free from the primary composite end point was 17.0 (95% confidence interval, 12.4 to 19.6) years with the combination therapy and 9.6 years (95% confidence interval, 8.4 to 10.7) with no treatment with any of these agents, corresponding to a gain in eventfree survival of 7.4 (95% confidence interval, 6.4 to 8.7) years. When assuming lower adherence and less pronounced efficacy of combination therapy, the gain in eventfree survival ranged from 5.3 years (95% confidence interval, 4.4 to 6.1) to 5.8 years (95% confidence interval, 4.8 to 6.8). CONCLUSIONS: Treatment with the combination of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and SGLT2 inhibitor in patients with albuminuric CKD without diabetes is expected to substantially increase kidney failure-free survival. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Benazepril for Advanced Chronic Renal Insufficiency, NCT00270426, and a Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (Dapa-CKD), NCT03036150.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Vart P, Vaduganathan M, Jongs N, et al. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes. Clin J Am Soc Nephrol. 2022. PMID: 36414316. doi:10.2215/CJN.08900722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。